CCI-007
Based on 1 Customer Validation
CCI-007 is a small molecule with cytotoxic activity against infant leukemia with MLL rearrangements, with IC50 values of 2.5-6.2 μM in sensitive cells.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 98.45%
- CAS No.: 939228-52-1
- Formule: C15H16N2O5S
- Masse moléculaire:336.36
-
Stockage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Apoptosis Compound Library
HY-L003
-
Anti-Cancer Compound Library
HY-L025
-
Covalent Screening Library
HY-L036
-
Anti-Blood Cancer Compound Library
HY-L079
-
Cell Death Library
HY-L162
-
Anti-Hematopathy Compound Library
HY-L171
-
Bioactive Compound Library Max
HY-L181
-
Covalent Screening Library Plus
HY-L036P
-
Bioactive Compound Library
HY-L001
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
Activité biologique
CCI-007 is a selective inhibitor of MLL-r, CALM-AF10 and SET-NUP214 leukemia[1].
Following CCI-007 treatment for 24h, significant mitochondrial depolarization was observed in PER-485 cells as evidenced by a shift in JC-1 signal. CCI-007 alters the characteristic MLL-r gene expression signature in sensitive cells with downregulation of the expression of HOXA9, MEIS1, CMYC and BCL2[1].
Resistance to CCI-007 can occur by upregulation of MLL target gene expression[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:PER-485, MOLM-13, MV4;11 cells.
-
Concentration:5 μM.
-
Incubation Time:24 h.
-
Result:Induced apoptosis.
Chemical Information
-
CAS No. 939228-52-1
-
Appearance Solid
-
Masse moléculaire 336.36
-
Formule C15H16N2O5S
-
Color Light yellow to yellow
-
SMILES
O=C(OCC)COC1=CC=C(/C=C(SC(N)=N2)\C2=O)C=C1OC
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Solvant et solubilité
DMSO : 83.33 mg/mL (247.74 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (6.18 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (271 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Klaartje Somers, et al. CCI-007, a novel small molecule with cytotoxic activity against infant leukemia with MLL rearrangements. Oncotarget. 2016 Jul 19;7(29):46067-46087. [Content Brief]
[2]. Klaartje Somers, et al. A novel small molecule that kills a subset of MLL-rearranged leukemia cells by inducing mitochondrial dysfunction. Oncogene. 2019 May;38(20):3824-3842. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.9730 mL | 14.8650 mL | 29.7301 mL | 74.3251 mL |
| 5 mM | 0.5946 mL | 2.9730 mL | 5.9460 mL | 14.8650 mL | |
| 10 mM | 0.2973 mL | 1.4865 mL | 2.9730 mL | 7.4325 mL | |
| 15 mM | 0.1982 mL | 0.9910 mL | 1.9820 mL | 4.9550 mL | |
| 20 mM | 0.1487 mL | 0.7433 mL | 1.4865 mL | 3.7163 mL | |
| 25 mM | 0.1189 mL | 0.5946 mL | 1.1892 mL | 2.9730 mL | |
| 30 mM | 0.0991 mL | 0.4955 mL | 0.9910 mL | 2.4775 mL | |
| 40 mM | 0.0743 mL | 0.3716 mL | 0.7433 mL | 1.8581 mL | |
| 50 mM | 0.0595 mL | 0.2973 mL | 0.5946 mL | 1.4865 mL | |
| 60 mM | 0.0496 mL | 0.2478 mL | 0.4955 mL | 1.2388 mL | |
| 80 mM | 0.0372 mL | 0.1858 mL | 0.3716 mL | 0.9291 mL | |
| 100 mM | 0.0297 mL | 0.1487 mL | 0.2973 mL | 0.7433 mL |
CCI-007 Related Classifications
HY-122698 Related Classifications
Powered by Bioz